THERADIAG Financial publications will be released after market close. This schedule is indicative and subject to change.
2015 Full-year sales Monday February 8, 2016
2015 Full-year results Thursday March 10, 2016
2016 First-half results Wednesday September 28, 2016
Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa Tracker® range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is developing new biomarkers based on microRNAs for the diagnosis and monitoring of rectal cancer, auto- immune and inflammatory diseases and HIV/AIDS. Theradiag is thus participating in the development of customized treatment, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has over 75 employees.
For more information about Theradiag, please visit our website: www.theradiag.com
Theradiag Investor Relations Fabienne François CFO +33 1 64 62 10 12 contact@theradiag.com | NewCap Financial communications/ investor relations Valentine Brouchot/ Pierre Laurent +33 1 44 71 94 94 theradiag@newcap.eu | Alize RP Press Caroline Carmagnol/ Florence Portejoie +33 1 44 54 36 64 theradiag@alizerp.com |
1/1
Theradiag SA issued this content on 2016-01-14 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 2016-01-14 16:51:09 UTC
Original Document: http://www.theradiag.com/en/wp-content/blogs.dir/3/files_mf/1452788208PR_Theradiag_14012016_2016Financialcalendar_VF.pdf
